107 related articles for article (PubMed ID: 17070062)
21. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
22. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs.
Trebbien R; Klarskov L; Olesen M; Holst JJ; Carr RD; Deacon CF
Am J Physiol Endocrinol Metab; 2004 Sep; 287(3):E431-8. PubMed ID: 15126240
[TBL] [Abstract][Full Text] [Related]
23. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
24. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
[TBL] [Abstract][Full Text] [Related]
25. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV.
Oefner C; Pierau S; Schulz H; Dale GE
Acta Crystallogr D Biol Crystallogr; 2007 Sep; 63(Pt 9):975-81. PubMed ID: 17704566
[TBL] [Abstract][Full Text] [Related]
26. Stereoselective synthesis of a MCHr1 antagonist.
Andersen D; Storz T; Liu P; Wang X; Li L; Fan P; Chen X; Allgeier A; Burgos A; Tedrow J; Baum J; Chen Y; Crockett R; Huang L; Syed R; Larsen RD; Martinelli M
J Org Chem; 2007 Dec; 72(25):9648-55. PubMed ID: 17997573
[TBL] [Abstract][Full Text] [Related]
27. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
[TBL] [Abstract][Full Text] [Related]
28. Effects of experimentally adopted sexual schemas on vaginal response and subjective sexual arousal: a comparison between women with sexual arousal disorder and sexually healthy women.
Middleton LS; Kuffel SW; Heiman JR
Arch Sex Behav; 2008 Dec; 37(6):950-61. PubMed ID: 18256919
[TBL] [Abstract][Full Text] [Related]
29. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Plouvier B; Beatch GN; Jung GL; Zolotoy A; Sheng T; Clohs L; Barrett TD; Fedida D; Wang WQ; Zhu JJ; Liu Y; Abraham S; Lynn L; Dong Y; Wall RA; Walker MJ
J Med Chem; 2007 Jun; 50(12):2818-41. PubMed ID: 17506538
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
[TBL] [Abstract][Full Text] [Related]
32. Potential protease inhibitors based on a functionalized cyclic sulfamide scaffold.
Zhong J; Gan X; Alliston KR; Lai Z; Yu H; Groutas CS; Wong T; Groutas WC
J Comb Chem; 2004; 6(4):556-63. PubMed ID: 15244417
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K
Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000
[TBL] [Abstract][Full Text] [Related]
34. Designing drugs for the treatment of female sexual dysfunction.
Brown AD; Blagg J; Reynolds DS
Drug Discov Today; 2007 Sep; 12(17-18):757-66. PubMed ID: 17826689
[TBL] [Abstract][Full Text] [Related]
35. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
[TBL] [Abstract][Full Text] [Related]
36. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
37. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
39. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
Charrier N; Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
Bioorg Med Chem Lett; 2009 Jul; 19(13):3664-8. PubMed ID: 19428244
[TBL] [Abstract][Full Text] [Related]
40. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
